Issues in anticoagulant therapy: Recent trials start to answer the tough questions

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 2, 2005, Pages 157-163

  Jaffer, Amir K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTEIN C; PROTEIN S; WARFARIN;

AGE; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ANTITHROMBIN III DEFICIENCY; BLEEDING DISORDER; BRAIN HEMORRHAGE; CANCER; CAUSE OF DEATH; CLINICAL TRIAL; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG SELF ADMINISTRATION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LIVER ADENOMA; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; PROTEIN DEFICIENCY; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; BLEEDING; CHEMICALLY INDUCED DISORDER; NEOPLASM; THROMBOEMBOLISM; VEIN THROMBOSIS;

CLINICAL TRIALS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; RECURRENCE; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 17844362741     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.2.157     Document Type: Review

References (26)

1. Kearon C. Long-term management of patients after venous thromboembolism. Circulation 2004; 110(suppl 1):1-10-1-18.
2. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332:1661-1665.
3. Linkins LA, Choit PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139:893-900.
4. Ridker PM, Goldhaber SZ, Danielson E, et al, for the PREVENT Investigators. Long-term low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348:1425-1434.
5. Kearon C, Ginsberg JS, Kovacs MJ, et al, for the Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349:631-639.
6. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91-99.
7. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995; 74:1055-1058.
8. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162:1729-1735.
9. Lee AY, Levine MN, Baker RI, et al, for the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146-153.
10. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100:269-277.
11. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A metaanalysis. Arch Intern Med 1995; 155:601-607.
12. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80:10-23.
13. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162:1729-1735.
14. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials (erratum in Arch Intern Med 1994; 154:2254) Arch Intern Med 1994; 154:1449-1457.
15. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993; 341:259-265.
16. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84:478-480.
17. Tinmouth AH, Morrow BH, Cruickshank MK, Moore PM, Kovacs MJ. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother 2001; 35:669-674.
18. Dotan ZA, Mor Y, Leibovitch I, et al. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol 2002; 168:610-614.
19. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003; 89:527-530.
20. Jaffer A, Ahmed M, Bragg L, et al. Safety and efficacy of using low-molecular-weight heparins to bridge patients on long-term warfarin [abstract]. J Thromb Haemost 2003; 1(suppl 1):1862.
21. Spyropoulos AC, Jenkins P, Bornikova L. A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation. Pharmacotherapy 2004; 24:649-658.
22. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164:1319-1326.
23. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110:1658-1663.
24. Dunn AS, Spyropoulos AC, Surko SP, Turpie AGG. Perioperative bridging therapy with enoxaparin in patients requiring interruption of long-term oral anticoagulant therapy: a multicenter cohort study [abstract 1761]. Blood 2004; 104:488a.
25. Spyropoulos AC, Turpie AGG, Dunn AS, et al, for the REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: results from the REGIMEN registry [abstract 709]. Blood 2004; 104:203a.
26. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004; 125:1642-1650.